Crohn's disease and ulcerative colitis patients to rally in Washington

NewsGuard 100/100 Score

The Crohn's & Colitis Foundation of America (CCFA) is traveling to Washington, DC June 14th-15th to build support for legislation aimed at better understanding, preventing and curing Crohn's disease and ulcerative colitis. Patients and their families will meet with key health committee members in the House and Senate over the two-day visit.

Crohn's disease and ulcerative colitis are difficult, chronic digestive diseases that primarily attack the small and large intestines, causing inflammation, ulceration, and several significant complications. Collectively they are known as inflammatory bowel disease (IBD).

CCFA says the main objective of the visit is to convince key members of Congress to pass the "IBD Bill" before Congress adjourns this year. "Last year's conference was a tremendous success but there is still much to be done in order to improve the quality of life for the estimated one million children and adults affected," said Rodger L. DeRose, president and chief executive officer of CCFA. "This federal legislation represents a significant advancement in gaining support for research, prevention and treatment for these challenging diseases."

If enacted, this legislation would expand IBD research at the National Institutes of Health, establish an IBD prevention program at the Centers for Disease Control and Prevention and require federal studies to investigate the challenges that IBD patients face when seeking insurance for physician-recommended IBD therapies or applying for Social Security Disability.

The Bill was introduced last year in the Senate (S. 491) by Senator Harry Reid (D-NV) and Senator Thad Cochran (R-MS), and in the House (H.R. 290) by Congresswoman Sue Kelly (R-NY) and Congressman Jesse Jackson, Jr. (D-IL). Since the introduction the Bill has gained 170 bipartisan co-sponsors in the House and 35 bipartisan co-sponsors in the Senate.

The remainder of the CCFA's time in Washington will include a presentation by Eugene Kestenbaum, Chairperson, CCFA National Board of Trustees, and DeRose, along with three prominent researchers. The presentation will focus on CCFA's strategic plan "Challenges in IBD Research," including progress in genetics and basic and clinical research. A legislative update will follow.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Limoncella apple polyphenol extract shines in IBD liver damage study